How the FDA Uses Patient-Reported Outcomes (PROs)
| |

How the FDA Uses Patient-Reported Outcomes (PROs)

How Is the FDA Using PROs? The FDA has identified PROs1, also known as patient-generated health data (PGHD), as a focus area for regulatory science, given limitations with data collected in a controlled clinical setting, that patients are the experts in living with their condition, and therefore the FDA increasingly seeks to understand how patients…

Dossier Development: Global Value Dossier (GVD) and Academy of Managed Care Pharmacy (AMCP) Dossier
| |

Dossier Development: Global Value Dossier (GVD) and Academy of Managed Care Pharmacy (AMCP) Dossier

Critical to ensuring market access success for your product or technology, global value dossiers and AMCP dossiers are utilized to communicate product value with an eye to the unique access and reimbursement influencers within the market. Your product’s GVD or AMCP dossier should be started early in development and updated frequently with new clinical evidence…